Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis

Abstract Background/Introduction Abbreviation of duration dual antiplatelet therapy (DAPT) (one or three months) has been recently proposed, especially for high-bleeding risk patients, after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Purpose The purpose the specific systematic review and meta-analysis was to compare 30-days versus longer (≥3 DAPT in patients undergoing PCI DES, focusing on ischemic bleeding events. Methods Three databases were screened eligible randomized-control trials. primary endpoint incidence net adverse clinical events (NACE), as they defined each trial. Secondary endpoints consisted major cardiovascular (MACE), all-cause mortality, myocardial infraction, stroke, stent-thrombosis, repeat revascularization bleeding. Results We included 4 RCTs a total 26,576 patients; 13,282 grouped DAPT, while remaining 13,294 allocated period DAPT. One-month did not significantly reduce NACE (odds ratio [OR]: 0.87, 95% confidence intervals [Cl]: 0.74–1.03); however bleedings reduced by 22% (OR: 0.78, Cl: 0.65–0.94). Mortality (stroke, thrombosis) affected. Conclusions Thirty-days affect NACEs. However, odds 22%. differ between two arms. Thus, could be considered safe feasible DES selected those risk. Forthcoming shed light optimal Funding Acknowledgement Type funding sources: None.